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Oral signs are frequently the first manifestation of autoimmune diseases. For this reason, dentists play an important role in the
detection of emerging autoimmune pathologies. Indeed, an early diagnosis can play a decisive role in improving the quality of
treatment strategies as well as quality of life. This can be obtained thanks to specific knowledge of oral manifestations of
autoimmune diseases. This review is aimed at describing oral presentations, diagnosis, and treatment strategies for systemic
lupus erythematosus, Sjögren syndrome, pemphigus vulgaris, mucous membrane pemphigoid, and Behcet disease.1. Introduction
Increasing evidence is emerging for a steady rise of autoim-
mune diseases in the last decades [1]. Indeed, the growth in
autoimmune diseases equals the surge in allergic and cancer
pathology; on the other hand, infections are shown to be less
frequent in the Western societies [2]. Oral manifestations of
autoimmune disease are frequently the primary sign of
autoimmune diseases [3]. The dentists can therefore play a
pivotal role in the detection and during the following
multidisciplinary treatment. Precise and early diagnosis
increases the efficiency and efficacy of treatment strategy
[4–6]. Therefore, the goal of our review is to present the most
common autoimmune diseases that show the first oral
clinical signs and symptoms which are a manifestation of
the general clinical disease. Our review is presenting details
over systemic lupus erythematosus, Sjögren syndrome, pem-
phigus vulgaris, mucous membrane pemphigoid, and Behcet
disease. Every single paragraph reviews the general condi-
tions, and in the second part, we discuss the diagnosis and
treatment strategies.2. Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a severe and chronic
autoimmune inflammatory disease of unknown etiopatho-
genesis and various clinical presentations. SLE mainly affects
women 8 times more likely than men. The worldwide preva-
lence of SLE ranges between 12 and 50 per 100,000, depend-
ing on location and ethnicity [7].
SLE is usually a chronic and progressive disease whose
dormancy and progress are fairly regular and in sequence.
There are cellular and cell-mediated processes involved in
the SLE, even though it has been speculated that the primary
involvement is mainly due to cell-mediated immunity and
consequential humoral involvement [8]. The immune com-
plex deposits in different organs triggering an inflammatory
reaction that leads to organ functional impairment typical
of the disease. In the pathogenesis of SLE, the activation
of type I IFN pathways, B and T cell dysfunction, and
presence of antinuclear antibodies were demonstrated [9].
Anti-DNA antibodies (deoxyribonucleic acid, antinuclear
antibodies) are found in the patients’ serum. The prolifer-
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some cases, there have been signs of antilymphocyte antibod-
ies. The etiopathogenesis of SLE takes also into account
genetic factors [8, 9].
Skin damage is the typical clinical sign of SLE, and it has
been recorded in 85% of the cases [8]. Symptoms can vary
from simple circular skin lesions to multiorgan impairment,
potentially fatal. The most recurrent skin lesion is severe ery-
thema on the surface of the skin exposed to light; also, oral
discoid lesions are one of the more prevalent presentations
of the disease. The so-called malar rash (or butterfly rush)
is located on the nose and cheeks, and the erythema is found
also on the finger tips. The healing process of these lesions
which present a central scar and area around shows recrudes-
cence very often. In SLE, we have involvement of joints, skin,
muscles, eyes, lungs, central nervous system, and kidneys. At
the joint level, arthralgia and arthritis are frequently associ-
ated with the advancement of SLE. The arthralgia has an
asymmetric presentation and migratory behaviour [7]. The
topography of joint manifestations is very wide. Indeed, it
can interest any articular surface mimicking the rheumatoid
arthritis. Deformities are generated by the inflammatory pro-
cess of the tendons rather than degeneration [7]. At the skin
level, purpuric manifestations and vitiligo can also be
observed [8]. Lesions of retinae, as vasculitis, may injury
the nerve fibres causing impairment or loss of vision. Renal
disease or lupus nephritis is a grave complication of SLE that
affects 30% of patients [10, 11]. The classical clinical manifes-
tation is represented by a regular round or slightly red
irregular area. This can be characterized by atrophy or the
presence of ulceration. The red area is characterized by
typical white radiating striae and telangiectasia. These signs
may resemble those of lichen planus, despite the lack of sym-
metry. Although the oral condition is not major, petechial
lesion and gingival bleeding such as desquamative gingivitis,
marginal gingivitis, or erosive mucosal lesions have been
reported in up to 40% of patients and may indicate serious
thrombocytopenia. Many SLE patients may present at the
same time Sjögren syndrome [8, 9, 12, 13].
2.1. Diagnosis. SLE diagnosis is based on a multiple-organ
condition and the study of antinuclear antibodies at a serum
level. The so-called LE cells can be detected in the blood
stream. LE cells are mature neutrophils that have swallowed
spherical inclusions produced by nuclear components and
other cellular elements [8]. Lupus lesions can be confused
with erythema multiforme lesions, lichen planus, and vesi-
culobullous lesions [7]. Moreover, the differential diagnosis
has to include lichenoid reactions to dental fillings, trau-
matic or smoker’s keratosis, and verrucous carcinoma
[13]. The demonstration of intact adjacent tissues towards
given lesions through histological and immunohistochemi-
cal confirmation is still the standard criterion for a defin-
itive diagnosis [8, 12–14].
2.2. Treatment and Prognosis. SLE management is based on
prevention, maintenance of states of remission and allevia-
tion of symptoms, and reversal of inflammation [7, 8, 15,
16]. Salicylates and FANS are used in the less severe cases.There are other drugs used, such as hydroxychloroquine
(an antimalarial), cortisones, and other immunosuppressants
such as azathioprine and cyclophosphamide [8]. High- and
medium-potency corticosteroids and calcineurin inhibitors
are used as topical therapies for cutaneous manifestation
[17]. Protection from sunlight is part of the strategy in order
to avoid flare-ups of skin manifestations [7]. The prognosis is
often good when the course of the disease is of an intermedi-
ate type and only few organs are involved. The disease can
also be fatal in the case of kidney conditions with hyperten-
sion and rapid evolution towards kidney failure that leads
to the patient’s death [8, 18–20].3. Sjögren Syndrome
Sjögren syndrome is an autoimmune disease affecting sali-
vary and lacrimal glands and causing a reduction of the secre-
tion activity due by lymphocytic infiltration and consequent
destruction of the exocrine glands [8]. The lower production
of saliva (hyposalivation) causes dryness in the mouth (xer-
ostomia); the deficiency of tears causes xerophthalmia.
Although the etiopathology of the Sjögren syndrome is
still unknown, humoral- and cell-mediated immunity phe-
nomena are involved in the process; as a matter of fact,
increased activation of B cells followed by immune com-
plex formation and autoantibody production plays impor-
tant roles [21]. Genetic and environmental factors can also
be part in the pathogenesis of the syndrome [13].
Sjögren syndrome affects 0.5–3% of the entire population
and is predominant in women compared to men (9 : 1 ratio).
Typically, Sjögren syndrome is detected around 50 years of
age. It is important to underline that there are two charac-
teristic surges: just after the menarche and after the men-
opause [13, 22, 23].
Some patients show clinical signs only confined to the
mouth and eyes, while others present a more substantial
autoimmune damage. 50% of the cases also have a different
autoimmune condition, such as rheumatoid arthritis or sys-
temic lupus erythematosus [8]. Damage to the glands with-
out the evidence of other autoimmune issues is defined as
primary Sjögren syndrome. The addition of an autoimmune
disease is referred to as secondary Sjögren syndrome [13, 24].
The main signs of the syndrome are related to the oral cavity
[8]. The xerostomia is responsible for creating different man-
ifestations of SS at the level of oral cavity. Lack of saliva pre-
disposes patients to develop tooth cavities. The lack of saliva
facilitates the accumulation of plaque and their clearance.
Edema and inflammations of the gingiva are frequent clinical
signs. Moreover, a salivary flow decrease can develop oppor-
tunistic infections. Candida is often detected because the lack
of lysozyme and immunoglobulins facilitates its develop-
ment. Radfar et al. and Bayetto and Logan showed an associ-
ation between Candida and the decreased stimulated salivary
flow rate [25, 26]. The Sjögren syndrome affects both major
and minor salivary glands. 50% of the cases show an increase
in volume, symmetrical on both sides, of the parotid glands.
The histological appearance of the hypertrophic glands is
characterized by the replacement of the gland tissue by
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islands [24].
In addition to oral symptoms, patients also present
irritation and dryness of the eyes, caused by xerophthal-
mia, as well as by photophobia. Nearly 20% of the patients
affected by Sjögren syndrome show signs of the Raynaud
phenomenon, a condition that affects fingers and toes [8].
Finally, patients affected by this disease may have arthralgia,
myalgia, and asthenia.
The conclusions of different epidemiological studies
claim, although newer studies are required to confirm this,
that genetical as well as environmental factors play a role in
the pathogenesis of the diseases [27, 28]. The syndrome is
often accompanied by lab data alteration. 90% of the patients
result positive to the rheumatoid factor, an anti-IgG antibody
in the patient’s serum. There are also other autoantibodies
such as anti-Sjögren A and anti-Sjögren B that can be found
in these patients [8].
3.1. Diagnosis. The diagnosis of Sjögren syndrome is basically
clinical, supported by oral presentation and laboratory inves-
tigations. During recent decades, many classification criteria
have been elaborated with the purpose to provide useful
guidance for diagnosis by clinicians. The classification made
by Shiboski et al. is generally utilized and also endorsed by
the American College of Rheumatology [29, 30].
The diagnosis of the syndrome can be confirmed when
two out of three of the following conditions are identified:
xerostomia, keratoconjunctivitis sicca, and rheumatoid
arthritis or another autoimmune disease [8]. Measuring the
salivary flow and carrying out a biopsy of the minor salivary
glands are two basic diagnostic investigation tests to detect
the syndrome [24]. Very often, the xerostomia generates sec-
ondary symptoms that can help the clinician to orientate the
diagnosis. Indeed, difficulties to speech and metallic sensa-
tion in the mouth are characteristic of xerostomia, as well
as burning sensation of the oral mucosae [24, 31].
The ophthalmologic test is necessary to detect keratocon-
junctivitis sicca. The lacrimal flow is measured by means of
special absorbing pads [8]. Damage to the corneas, instead,
requires further specific analysis. In most cases, the disease
has a chronic and benign progress; however, these patients
are exposed to a high risk to develop more serious clinical
autoimmune issues: lymphoma and Waldenström macro-
globulinemia. Periodical check-ups are mandatory in order
to control and prevent the risks [8, 32, 33].
3.2. Treatment and Prognosis. The treatment for the Sjögren
syndrome is mainly clinical. The use of FANS has a beneficial
effect on arthritis. In major cases, corticosteroid and immu-
nosuppressive drugs may be needed. Xerostomia can be reg-
ulated by using saliva substitutes such as sprays/gel or by
installing an air humidifier. Sugar-free chewing gums may
be useful to alleviate the feeling of dryness in the oral cavity,
as well as hyperstimulate the salivary production. Methylcel-
lulose artificial tears can alleviate xerophthalmia. Very often,
Sjögren syndrome is accompanied by candidiasis produced
by Candida albicans. This will require antimycotic treatment
[13, 33]. Salivary secretion can be increased by takingpilocarpine. At a dental level, teeth and gums must be pro-
tected from the collateral damage caused by xerostomia [8].
Intensive domiciliary as well as professional oral hygiene care
is mandatory to avoid complications due to teeth decay or
root canal inflammation [34].
4. Pemphigus Vulgaris
Pemphigus vulgaris is a chronic immunomediated disorder.
This disease affects the skin and mucosa. Patients affected
by pemphigus have immune globulin G autoantibody
against desmosomal components like desmoglein-1 and
desmoglein-3 [35]. This alters the properties of adhesion
cell molecules, producing intraepithelial blisters between
the Malpighian epitheliocytes. This phenomenon is called
acantolysis of suprabasilar cheratynocites [8, 35].
Although epidemiologically there is no evidence of
gender predilection, some studies reported a slight preva-
lence in women [13]. All ages can be affected, though
the highest number of cases is observed in patients in their
40s and 50s [8, 13].
The etiology would seem to be linked to genetic and eth-
nic factors. The lesions seem to be triggered by different
inputs like physical agents, viruses, hormones, drugs, and
stress [8, 13].
In over 50% of cases, the first signs of the disease arise in
the oral mucosa. Although there is no area predilection, the
lesions could be located at the buccal mucosae, soft palate,
lower lip, and tongue and, less frequently, at the gingiva
[36]. Oral lesions can range from fairly superficial ulcers to
small vesicles or blisters. In the oral cavity, the bubbles rap-
idly break, leaving a painful erosion producing burning sen-
sation [13]. The size of the ulcers is extremely variable. It
can be noticed that a detachment of a large area of the surface
with the formation of blisters can occur by exerting a slight
pressure on the epithelium of these patients. This phenome-
non is referred to as the Nikolsky phenomenon [8].
Pemphigus skin lesions are subsequent to oral manifesta-
tions. They can arise as simple rashes to erosions, vesicles,
blisters, or ulcers. Microscopic examination highlights super-
ficial epithelial damage with the intact basal layer adhering to
the basal membranes [8]
4.1. Diagnosis. The pemphigus can be easily confused with
other disorders that present lesions like aphthae, lichen pla-
nus, candidiasis, and pemphigoid. Often, pemphigus is asso-
ciated with other autoimmune clinical situations such as the
Sjögren syndrome, rheumatoid arthritis, and systemic lupus
erythematosus [37, 38]. As a matter of fact, clinical, histo-
pathological, and, in particular, direct and indirect immuno-
fluorescence is mandatory to perform an efficient differential
diagnosis. Direct immunofluorescence is performed on the
tissue and highlights the local cellular damage (visualization
takes place through a special microscope that highlights the
fluorescence inside the spinous layer). In the indirect type,
the antibodies are detected in the patient’s serum [8, 39].
4.2. Treatment and Prognosis. The pemphigus is a pathology
that involves primarily dermatologists although dentists can
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well as in the management of oral manifestations. The treat-
ment involves the administration of high-dose corticoste-
roids. In addition to these, immunosuppressive drugs such
as azathioprine, cyclophosphamide, cyclosporine, and meth-
otrexate are sometimes used. Recently, the use of rituximab
has been proposed showing promising results [40, 41]. The
titration of circulating antibodies is carried out to evaluate
the progress of the disease. In fact, high antibody rates
correspond to the most destructive phases of the disease.
Their evaluation is also used to check the effectiveness of
the treatment [8].
5. Mucous Membrane Pemphigoid
Mucous membrane pemphigoid (MMP) is a group of
immune-mediated chronic blistering conditions. The oral
mucosa is targeted as well as genital, conjunctival, and skin
mucous membranes [8]. The autoantibodies mostly IgA
and IgG are located, together with the C3 complement, on
the mucosae as well as on epithelial basal membranes [35].
The most affected area is the gingiva, almost 94% of the
cases [35], where the pemphigoid lesions give rise to a clinical
condition called desquamative gingivitis. It has been said that
desquamative gingivitis is not, per se, diagnostic. The lesions
show as simple erythema or true ulcerations affecting both
the fixed gingiva and the adherent gingiva. Very often, this
lesion is confounded with periodontal disease.
However, lesions can also occur in other areas of the oral
cavity including the palate, buccal mucosae, lips, tongue, and
pharynx.
The symptoms associated with these conditions go from
burning sensation and bleeding to masticatory impairment
[35]. Pemphigoid blisters are less brittle than those seen in
pemphigus and can remain intact in the oral cavity for up
to 48 hours [8, 42].
5.1. Diagnosis. The diagnosis of mucous membrane pemphi-
goid is based on clinical and histological samples. The histo-
logic examination shows the detachment of the epithelium
from the underlying connective tissue. Direct immunofluo-
rescence is diriment when there are doubtful histological
samples showing a linear involvement at the level of the basal
membrane. The immunofluorescence is particularly useful in
the differential diagnosis with pemphigus and lichen as well
as with periodontal disease and SLE. Epithelial degeneration
is not observed; the connective tissue appears pervaded by an
intense inflammatory infiltrate mainly consisting of plasma
cells and eosinophils [8].
5.2. Treatment and Prognosis. The mucous membrane
pemphigoid is a chronic disease that requires a continuous
treatment strategy although the prognosis is benign. Some-
times, the lesions can only be localized to the gums; in other
cases, the oral condition is wider. In less severe cases, the
lesions can be treated by topical corticosteroid gel application
although in some selected cases, it is coupled with dapsone
(diaminodiphenyl sulfone). In the most severe forms, the
treatment must be carried out systemically. Often, thepathology can be difficult to resolve, tending to respond
rather late to therapy. It is crucial to monitor the presence
of eye lesions to prevent ocular damage, such as injury to
the cornea, conjunctiva, or eyelids [13, 35].
6. Behcet Disease
Behcet syndrome is an autoimmune, multisystemic disease of
unknown etiology. It is typically characterized by at least two
of the three key typical factors: oral ulcers, genital ulcers, and
eye inflammation. Although its original definition is linked to
dermatologic pathology, Behcet disease is often characterized
by neurological and vascular involvement. It usually affects
individuals in their 30s and shows no evidence of gender pre-
dilection. The greatest incidence of the disease is observed in
Mediterranean and Asian populations with a marked preva-
lence in Turkey. The demonstration of an autoimmune gen-
esis is given by the presence of antimucous autoantibodies,
together with the association of the disease with the HLA
configurations B5 and B51 [8, 43].
The mucocutaneous lesions are very often the first sign of
the presence of Behcet syndrome. Their recognition is a key
factor for early diagnosis, and they permit a more favourable
prognosis [44]. The oral lesions are ulcers of the oral mucosae
indistinguishable from the conventional aphthae of the oral
mucosa. They are painful and characterized by cyclic presen-
tation. They are localized at the lips, buccal mucosa, soft pal-
ate, and tongue. At the beginning, the lesion shows as an
erythematous lesion, followed by an evolution in ulcers.
Their dimensions can vary from few millimeters to centime-
ters [8, 44].
The genital ulcers are smaller and are located at the level
of the scrotum, on the base of the penis, or on the labia
majora.
Ocular lesions are present in 30–70% of the cases [43].
They show up as an initial form of photophobia, followed
by uveitis and conjunctivitis. In some cases, they were found
to be associated with glaucoma and cataract [43].
The skin lesions have a papular or pustular appearance
and are mainly localized to the trunk or limbs.
6.1. Diagnosis. It has been said that there are not pathogno-
monic laboratory findings [43]. In order to diagnose the Beh-
cet syndrome, according to the ISG criteria [45], at least two
of the main features (oral, genital, or ocular lesions) must be
present when another clinical explanation is excluded.
Indeed, the differential diagnosis is a challenge considering
that oral aphthous lesions are very common in the general
population. Moreover, aphthous lesions are linked to HIV,
Crohn’s disease, sarcoidosis, and SLE, given that the dual-
site-specific ulcerations seem to be the unique sign used to
differentiate the Behcet syndrome from different pathologies
cited above [43].
6.2. Treatment and Prognosis. The treatment of Behcet syn-
drome is based on the use of local and systemic cortisones
per se or coupled with immunosuppressant drugs. The use
of immunosuppressive drugs is justified by the lack of pre-
vention of relapses due to the monocorticosteroid treatment
5Journal of Immunology Researchstrategy [43]. The main objective of Behcet syndrome patient
care is to treat in time the oral mucocutaneous lesions in
order to hinder the progression of the disease and to prevent
the irreversible organ involvement in particular during the
active phase [44]. Behcet syndrome could be fatal especially
in the case of vascular involvement: aneurism rupture and
thrombosis are the main causes of death.Conflicts of Interest
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